Your browser doesn't support javascript.
loading
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey.
Swartz, Michael D; DeSantis, Stacia M; Yaseen, Ashraf; Brito, Frances A; Valerio-Shewmaker, Melissa A; Messiah, Sarah E; Leon-Novelo, Luis G; Kohl, Harold W; Pinzon-Gomez, Cesar L; Hao, Tianyao; Zhang, Shiming; Talebi, Yashar; Yoo, Joy; Ross, Jessica R; Gonzalez, Michael O; Wu, Leqing; Kelder, Steven H; Silberman, Mark; Tuzo, Samantha; Pont, Stephen J; Shuford, Jennifer A; Lakey, David; Boerwinkle, Eric.
Affiliation
  • Swartz MD; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • DeSantis SM; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Yaseen A; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Brito FA; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Valerio-Shewmaker MA; The University of Texas Health Science Center in Houston, School of Public Health in Brownsville, Brownsville, Texas, USA.
  • Messiah SE; The University of Texas Health Science Center in Houston, School of Public Health in Dallas, Dallas, Texas, USA.
  • Leon-Novelo LG; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Kohl HW; The University of Texas Health Science Center in Houston, School of Public Health in Austin, Austin, Texas, USA.
  • Pinzon-Gomez CL; The University of Texas at Austin, College of Education, Department of Kinesiology and Health Education, Austin, Texas, USA.
  • Hao T; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Zhang S; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Talebi Y; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Yoo J; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Ross JR; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Gonzalez MO; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Wu L; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Kelder SH; The University of Texas Health Science Center in Houston, School of Public Health in Houston, Houston, Texas, USA.
  • Silberman M; The University of Texas Health Science Center in Houston, School of Public Health in Austin, Austin, Texas, USA.
  • Tuzo S; Clinical Pathology Laboratories, Austin, Texas, USA.
  • Pont SJ; Clinical Pathology Laboratories, Austin, Texas, USA.
  • Shuford JA; Texas Department of State Health Services, Austin, Texas, USA.
  • Lakey D; Texas Department of State Health Services, Austin, Texas, USA.
  • Boerwinkle E; University of Texas System, Office of Health Affairs, Austin, Texas, USA.
J Infect Dis ; 227(2): 193-201, 2023 01 11.
Article in En | MEDLINE | ID: mdl-35514141
Understanding the duration of antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody Response Survey (Texas CARES) with at least 1 nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n = 4553) with 1 to 3 antibody tests over 11 months (1 October 2020 to 16 September 2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days postinfection, and predicts individuals may remain antibody positive from natural infection beyond 500 days depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Infect Dis Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Prognostic_studies Limits: Humans Country/Region as subject: America do norte Language: En Journal: J Infect Dis Year: 2023 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos